TokenPost·
Edwards Says PASCAL Outperformed Medical Therapy on Tricuspid Trial Endpoint
At one year, 80% of PASCAL-treated patients had moderate or lower tricuspid regurgitation, compared with 30% of control patients.
More news
- TokenPostJane Street Becomes Fifth Authorized Participant for Hashdex’s NCIQ ETF
- TokenPostMIG ETF Has a Scheduled Nov. 5 Payable Date
- TokenPostAnthropic IPO Valuation Expectations Fall to $1.5 Trillion-$1.6 Trillion
- TokenPostNapco Sets Fiscal 2027 Equipment Margin Target at 26% to 27%
- TokenPostBTCPay Founder Says Public Version 2.4.7 Was Not Attacked
- TokenPostMarvell-Lumentum deal targets AI optics, adding $60 billion to market opportunity